| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 2649 | 2021 |
| PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial F Lordick, K Ott, BJ Krause, WA Weber, K Becker, HJ Stein, S Lorenzen, ... The lancet oncology 8 (9), 797-805, 2007 | 991 | 2007 |
| 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 WP Fendler, M Eiber, M Beheshti, J Bomanji, F Ceci, S Cho, F Giesel, ... European journal of nuclear medicine and molecular imaging 44 (6), 1014-1024, 2017 | 886 | 2017 |
| Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial WP Fendler, J Calais, M Eiber, RR Flavell, A Mishoe, FY Feng, ... JAMA oncology 5 (6), 856-863, 2019 | 838 | 2019 |
| Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT M Eiber, K Herrmann, J Calais, B Hadaschik, FL Giesel, M Hartenbach, ... Journal of Nuclear Medicine 59 (3), 469-478, 2018 | 680 | 2018 |
| Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction K Ott, WA Weber, F Lordick, K Becker, R Busch, K Herrmann, H Wieder, ... Journal of Clinical Oncology 24 (29), 4692-4698, 2006 | 578 | 2006 |
| Spect/ct AK Buck, S Nekolla, S Ziegler, A Beer, BJ Krause, K Herrmann, ... Journal of Nuclear Medicine 49 (8), 1305-1319, 2008 | 466 | 2008 |
| The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer BJ Krause, M Souvatzoglou, M Tuncel, K Herrmann, AK Buck, C Praus, ... European journal of nuclear medicine and molecular imaging 35 (1), 18-23, 2008 | 449 | 2008 |
| EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) C Kratochwil, WP Fendler, M Eiber, R Baum, MF Bozkurt, J Czernin, ... European journal of nuclear medicine and molecular imaging 46 (12), 2536-2544, 2019 | 415 | 2019 |
| Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors TA Hope, EK Bergsland, MF Bozkurt, M Graham, AP Heaney, K Herrmann, ... Journal of Nuclear Medicine 59 (1), 66-74, 2018 | 382 | 2018 |
| E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET F Ceci, DE Oprea-Lager, L Emmett, JA Adam, J Bomanji, J Czernin, ... European journal of nuclear medicine and molecular imaging 48 (5), 1626-1638, 2021 | 381 | 2021 |
| Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 … TA Hope, M Eiber, WR Armstrong, R Juarez, V Murthy, C Lawhn-Heath, ... JAMA oncology 7 (11), 1635-1642, 2021 | 363 | 2021 |
| PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 WP Fendler, M Eiber, M Beheshti, J Bomanji, J Calais, F Ceci, SY Cho, ... European journal of nuclear medicine and molecular imaging 50 (5), 1466-1486, 2023 | 347 | 2023 |
| Radiotheranostics in oncology: current challenges and emerging opportunities L Bodei, K Herrmann, H Schöder, AM Scott, JS Lewis Nature Reviews Clinical Oncology 19 (8), 534-550, 2022 | 336 | 2022 |
| First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary … K Herrmann, M Schottelius, C Lapa, T Osl, A Poschenrieder, H Hänscheid, ... Journal of nuclear medicine 57 (2), 248-251, 2016 | 311 | 2016 |
| 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage … J Calais, J Czernin, M Cao, AU Kishan, JV Hegde, N Shaverdian, ... Journal of Nuclear Medicine 59 (2), 230-237, 2018 | 306 | 2018 |
| Radiotheranostics: a roadmap for future development K Herrmann, M Schwaiger, JS Lewis, SB Solomon, BJ McNeil, ... The Lancet Oncology 21 (3), e146-e156, 2020 | 302 | 2020 |
| [177Lu] Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated … S Singh, D Halperin, S Myrehaug, K Herrmann, M Pavel, PL Kunz, ... The lancet 403 (10446), 2807-2817, 2024 | 299 | 2024 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 294 | 2019 |
| Prostate-specific membrane antigen ligands for imaging and therapy M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ... Journal of Nuclear Medicine 58 (Supplement 2), 67S-76S, 2017 | 285 | 2017 |
